H-ARG-ARG-ARG-PRO-ARG-PRO-PRO-TYR-LEU-PRO-ARG-PRO-ARG-PRO-PRO-PRO-PHE-PHE-PRO-PRO-ARG-LEU-PRO-PRO-ARG-ILE-PRO-PRO-GLY-PHE-PRO-PRO-ARG-PHE-PRO-PRO-ARG-PHE-PRO-NH2
| 中文名稱 | H-ARG-ARG-ARG-PRO-ARG-PRO-PRO-TYR-LEU-PRO-ARG-PRO-ARG-PRO-PRO-PRO-PHE-PHE-PRO-PRO-ARG-LEU-PRO-PRO-ARG-ILE-PRO-PRO-GLY-PHE-PRO-PRO-ARG-PHE-PRO-PRO-ARG-PHE-PRO-NH2 |
|---|---|
| 中文同義詞 | H-ARG-ARG-ARG-PRO-ARG-PRO-PRO-TYR-LEU-PRO-ARG-PRO-ARG-PRO-PRO-PRO-PHE-PHE-PRO-PRO-ARG-LEU-PRO-PRO-ARG-ILE-PRO-PRO-GLY-PHE-PRO-PRO-ARG-PHE-PRO-PRO-ARG-PHE-PRO-NH2;抗菌肽PR 39 (PORCINE) |
| 英文名稱 | PR 39 (PORCINE) |
| 英文同義詞 | M.W. 4719.64 C229H346N70O40;L-Prolinamide, L-arginyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-tyrosyl-L-leucyl-L-prolyl-L-arginyl-L-prolyl-L-arginyl-L-prolyl-L-prolyl-L-prolyl-L-phenylalanyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-leucyl-L-prolyl-L-prolyl-L-arginyl-L-isoleucyl-L-prolyl-L-prolylglycyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-L-prolyl-L-prolyl-L-arginyl-L-phenylalanyl-;PR 39 (PORCINE);PR-39, PORCINE, SYNTHETIC;PR 39 |
| CAS號 | 139637-11-9 |
| 分子式 | C229H345N69O41 |
| 分子量 | 4720.6273 |
| EINECS號 | |
| 相關(guān)類別 | Cytokine signaling |
| Mol文件 | 139637-11-9.mol |
| 結(jié)構(gòu)式 |  |
H-ARG-ARG-ARG-PRO-ARG-PRO-PRO-TYR-LEU-PRO-ARG-PRO-ARG-PRO-PRO-PRO-PHE-PHE-PRO-PRO-ARG-LEU-PRO-PRO-ARG-ILE-PRO-PRO-GLY-PHE-PRO-PRO-ARG-PHE-PRO-PRO-ARG-PHE-PRO-NH2 性質(zhì)
| 儲存條件 | Desiccate at -20°C |
|---|---|
| 溶解度 | 溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。 |
| 形態(tài) | 粉末 |
H-ARG-ARG-ARG-PRO-ARG-PRO-PRO-TYR-LEU-PRO-ARG-PRO-ARG-PRO-PRO-PRO-PHE-PHE-PRO-PRO-ARG-LEU-PRO-PRO-ARG-ILE-PRO-PRO-GLY-PHE-PRO-PRO-ARG-PHE-PRO-PRO-ARG-PHE-PRO-NH2 用途與合成方法
PR-39, shown to selectively affect proteasomemediated protein degradation in vivo, alters the shape of the 20S and 26S cylinder and affects the binding of 19S caps in a reversible manner. PR-39 specifically blocks degradation of IκBα and HIF-1α by the proteasome.
PR-39 (100 nM) blocks TNF-α-induced (1 ng/mL; for 20 minutes) activation of VCAM-1 (2 hours) and ICAM-1 (8 hours) expression in human umbilical vein endothelial cells (HUVEC).
PR-39 (10 μM) does not affect the ability to proliferate of ECV304 cell. PR39 is able to inhibit IκBα degradation without significantly affecting overall protein degradation in cells.
PR-39 (10 mg/kg, intravenously; 1 hour before Caerulein of 50μg/kg, ip) blocks IκBα degradation and NF-κB-dependent transcription in the mouse pancreas after induction of acute pancreatitis.
PR-39 (1 μg/kg/day; 7-day intraperitoneal infusion) demonstrates significantly small infarct in C57BL/6 mice.